Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
Шарҳ мақола

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

X. XiaThe Second Clinical Medical School, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, ChinaZongxin YangThe Second Clinical Medical School, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, ChinaQisi LuForesea Life Insurance Guangzhou General Hospital, Guangzhou, 511300, ChinaZhenyun LiuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, ChinaLei WangDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, ChinaJinwen DuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, ChinaYuhua LiDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. [email protected]Dong‐Hua YangNew York College of Traditional Chinese Medicine, Mineola, NY, 11501, USA. [email protected]Shaojie WuDepartment of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China. [email protected]
2024en
ABI

Аннотация

In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment efficacy. Current CAR-T therapies are particularly discouraging for solid tumor treatment. The immunosuppressive microenvironment of tumors affects CAR-T cells, limiting the treatment's effectiveness and safety. Therefore, enhancing CAR-T cell infiltration capacity and resolving the immunosuppressive responses within the tumor microenvironment could boost the anti-tumor effect. Specific strategies include structurally altering CAR-T cells combined with targeted therapy, radiotherapy, or chemotherapy. Overall, monitoring the tumor microenvironment and the status of CAR-T cells is beneficial in further investigating the viability of such strategies and advancing CAR-T cell therapy.

Ҳали таржима қилинмаган

Идентификаторлар

Иқтибослар ва манбалар

2 та иқтибос0 та фойдаланилган манба